Themis Medicare announced the add on approval for drug Viralex by the Drug Controller General of India (DCGI) for the treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties. Earlier Viralex was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two randomized controlled trials (RCT) in 499 Indian patients.

Inosine Pranobex is in clinical use for >50 years since its first approval internationally. It is currently marketed in >70 countries across the world including many advanced countries for the treatment of several viral diseases with established efficacy and safety profile.

Viralex strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body's immune response to various viral infections.

NK cells are the first-line defence against viral infections. Viralex enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Speaking on the development, Dr. Sachin Patel, Managing Director& CEO of Themis Medicare said, "Our endeavour has always been to develop medicines that address unmet medical needs and make healthcare far, far more effective for patient benefits".